person
David P.
- Country
- France
- Department
- Thoracy oncology unit
Research Overview
assignment
47
Clinical Trials ·
- Phase 2 Study of DS-1062a in Advanced Non-Small Cell Lung Cancer with Biomarker Analysis for Therapy Response
- Dose-Escalation Study of Zongertinib in Patients with Advanced Non-Small Cell Lung Cancer and Solid Tumors with HER2 Aberrations
- Evaluation of Trastuzumab Deruxtecan with Immunotherapy and Chemotherapy in First-Line Treatment of HER2-Overexpressing Advanced Non-Small Cell Lung Cancer
location_city
1
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
295
Sites with multiple studies
Has run more than one trial at 295 of 506 partner sites.
Specializations
Non-Small Cell Lung Cancer Expertise
Specializes in treating advanced non-small cell lung cancer with particular focus on tumors with specific genetic mutations including EGFR, HER2, and ALK alterations.
- Targeted Therapies
- Mutation-Specific Treatments
- Advanced Stage Disease Management
Novel Therapeutic Approaches
Investigates innovative treatment combinations including antibody-drug conjugates, immunotherapy agents, and novel targeted therapies for lung cancer patients.
- Combination Therapies
- Immunotherapy Applications
- Resistance Mechanisms
Small Cell Lung Cancer Research
Conducts research in extensive-stage small cell lung cancer treatment approaches, including evaluation of new therapeutic combinations and strategies for disease management.
- First-line Treatments
- Disease Progression Monitoring
- Treatment Response Assessment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.